These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 23359692)

  • 1. Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist.
    Rick FG; Abi-Chaker A; Szalontay L; Perez R; Jaszberenyi M; Jayakumar AR; Shamaladevi N; Szepeshazi K; Vidaurre I; Halmos G; Krishan A; Block NL; Schally AV
    Proc Natl Acad Sci U S A; 2013 Feb; 110(7):2617-22. PubMed ID: 23359692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia.
    Rick FG; Schally AV; Block NL; Nadji M; Szepeshazi K; Zarandi M; Vidaurre I; Perez R; Halmos G; Szalontay L
    Proc Natl Acad Sci U S A; 2011 Mar; 108(9):3755-60. PubMed ID: 21321192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re: Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing Peptide antagonist.
    Kaplan SA
    J Urol; 2013 Nov; 190(5):1956. PubMed ID: 24120818
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist.
    Atala A
    J Urol; 2013 Oct; 190(4):1436. PubMed ID: 24029360
    [No Abstract]   [Full Text] [Related]  

  • 5. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
    Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M
    Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psoralea corylifolia L. extract ameliorates benign prostatic hyperplasia by regulating prostate cell proliferation and apoptosis.
    Kim HJ; Jin BR; An HJ
    J Ethnopharmacol; 2021 Jun; 273():113844. PubMed ID: 33485982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice.
    Jungwirth A; Galvan G; Pinski J; Halmos G; Szepeshazi K; Cai RZ; Groot K; Schally AV
    Prostate; 1997 Aug; 32(3):164-72. PubMed ID: 9254895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormone-releasing hormone in shrinking experimental benign prostatic hyperplasia.
    Rick FG; Schally AV; Block NL; Abi-Chaker A; Krishan A; Szalontay L
    Prostate; 2013 Jun; 73(8):873-83. PubMed ID: 23280565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quisqualis indica Improves Benign Prostatic Hyperplasia by Regulating Prostate Cell Proliferation and Apoptosis.
    Ub Wijerathne C; Park HS; Jeong HY; Song JW; Moon OS; Seo YW; Won YS; Son HY; Lim JH; Yeon SH; Kwun HJ
    Biol Pharm Bull; 2017 Dec; 40(12):2125-2133. PubMed ID: 28943529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
    Pinski J; Reile H; Halmos G; Groot K; Schally AV
    Cancer Res; 1994 Jan; 54(1):169-74. PubMed ID: 7903203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II inhibit tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma.
    Koppán M; Halmos G; Arencibia JM; Lamharzi N; Schally AV
    Cancer; 1998 Oct; 83(7):1335-43. PubMed ID: 9762934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antagonists of bombesin/gastrin-releasing peptides as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
    Pinski J; Halmos G; Szepeshazi K; Schally AV
    Cancer; 1993 Dec; 72(11):3263-70. PubMed ID: 8242552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage.
    Rick FG; Szalontay L; Schally AV; Block NL; Nadji M; Szepeshazi K; Vidaurre I; Zarandi M; Kovacs M; Rekasi Z
    J Urol; 2012 Apr; 187(4):1498-504. PubMed ID: 22341819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of HER expression and transactivation in human prostate cancer cells by a targeted cytotoxic bombesin analog (AN-215) and a bombesin antagonist (RC-3095).
    Sotomayor S; Muñoz-Moreno L; Carmena MJ; Schally AV; Sánchez-Chapado M; Prieto JC; Bajo AM
    Int J Cancer; 2010 Oct; 127(8):1813-22. PubMed ID: 20099275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of growth of human malignant glioblastoma in nude mice by antagonists of bombesin/gastrin-releasing peptide.
    Kiaris H; Schally AV; Sun B; Armatis P; Groot K
    Oncogene; 1999 Nov; 18(50):7168-73. PubMed ID: 10597318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baicalin alleviates benign prostate hyperplasia through androgen-dependent apoptosis.
    Jin BR; An HJ
    Aging (Albany NY); 2020 Feb; 12(3):2142-2155. PubMed ID: 32018227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways.
    Plonowski A; Schally AV; Varga JL; Rekasi Z; Hebert F; Halmos G; Groot K
    Prostate; 2000 Jul; 44(2):172-80. PubMed ID: 10881027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prevention and treatment effects of tanshinone IIA on oestrogen/androgen-induced benign prostatic hyperplasia in rats.
    Wang C; Du X; Yang R; Liu J; Xu D; Shi J; Chen L; Shao R; Fan G; Gao X; Tian G; Zhu Y; Zhang J
    J Steroid Biochem Mol Biol; 2015 Jan; 145():28-37. PubMed ID: 25290459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II.
    Kahán Z; Sun B; Schally AV; Arencibia JM; Cai RZ; Groot K; Halmos G
    Cancer; 2000 Mar; 88(6):1384-92. PubMed ID: 10717621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin analog RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer line in nude mice.
    Pinski J; Halmos G; Schally AV
    Cancer Lett; 1993 Jul; 71(1-3):189-96. PubMed ID: 8103419
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.